Oral Cancer Treatment Market

Global Oral Cancer Treatment Market Overview

Oral Cancer Treatment Market Size was valued at USD 1.93 Billion in 2023. The Global Oral Cancer Treatment industry is projected to grow from USD 2.04 Billion in 2024 to USD 3.20 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.50% during the forecast period (2024 - 2032). Increasing prevalence of oral cancer, surge in global geriatric population, and growing government expenditure on healthcare are the key market drivers enhancing the market growth.

The rising incidence of oral cancer will likely contribute to the expansion of the Oral Cancer Treatment Market. Increasing rates of oral cancer risk factors, such as smoking, alcohol consumption, and human papillomavirus (HPV) infection, are also propelling the demand for oral cancer treatments. In addition, the availability of advanced technologies and treatments, such as surgery, radiation therapy, chemotherapy, and targeted therapy, is driving the Oral Cancer Treatment Market. 

Increases in the global geriatric population are anticipated to present dental caries treatment market participants with lucrative growth opportunities. For example, dentures, a lack of dexterity, a transition from complex to simple carbohydrates, and inadequate oral hygiene increase the risk of root caries in the elderly. 

In addition, the growing understanding of the significance of early detection and diagnosis of oral cancer is driving the demand for screening and diagnostic tests such as biopsies, imaging tests, and blood tests. This is anticipated to contribute to the growth of the Oral Cancer Treatment Market, as early detection and treatment can improve patient outcomes and survival rates. 

Major market participants are investing heavily in R&D to expand their product lines, which will help the oral cancer treatment market expand even further. Key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration between organizations are among the strategic measures that market participants are implementing to expand their global footprint. Competitors in the industry of oral cancer treatment must provide cost-effective products in order to expand and endure in an increasingly competitive and expanding market.

July 2023:Biocon Foundation, in collaboration with four other healthcare institutions, will launch the Oral Potentially Malignant Disorders (OPMD) Atlas Project in July 2023 in order to develop a multidimensional data-centric platform for the prevention, early detection, and treatment of oral malignancies. The Atlas Project seeks to evaluate and precisely deploy point-of-care (PoC) diagnosis systems in the national healthcare system for accurate screening, detection, and prognosis of oral cancers.

Oral Cancer Treatment Market Trends

• Increase in prevalence of oral cancer to boost market growth

The rising prevalence of oral cancer is likely to support the growth of the Oral Cancer Treatment Market. According to the American Cancer Society, the incidence of oral and oropharyngeal cancer has been increasing in recent years. In 2021, an estimated 54,010 people in the United States will be diagnosed with oral cavity or oropharyngeal cancer, and an estimated 10,850 will die from the disease. The increasing prevalence of risk factors for oral cancer, such as smoking, alcohol consumption, and human papillomavirus (HPV) infection, is also driving the demand for oral cancer treatments. Additionally, the availability of advanced technologies and treatments, such as surgery, radiation therapy, chemotherapy, and targeted therapy, is contributing to the growth of the Oral Cancer Treatment Market. Furthermore, the rising awareness about the importance of early detection and diagnosis of oral cancer is driving the demand for screening and diagnostic tests, such as biopsies, imaging tests, and blood tests. This is expected to further support the growth of the Oral Cancer Treatment Market, as early detection and treatment can improve the outcomes and survival rates for patients with oral cancer. According to the National Cancer Institute, in the United States in 2021, there were an estimated 53,260 new cases of oral and oropharyngeal cancer and an estimated 10,750 deaths from these cancers.

Global geriatric population increase is anticipated to offer players in the dental caries treatment market with lucrative growth prospects. For instance, dentures, a lack of dexterity, a switch from complex to simple carbohydrates, and poor oral hygiene put the elderly at risk for developing root caries. According to the American Dental Association, older persons are more likely to develop root caries as a result of increased xerostomia-producing medication use as well as increased gingival recession, which exposes root surfaces. More than 50% of people 75 years and older have at least one tooth affected by root caries.

Dental technology developments are anticipated to provide companies in the dental caries treatment market with lucrative growth prospects. For instance, Pearl raised US$ 11 million in May 2019 to use AI to evaluate dental scans (Artificial Intelligence). According to the company, it will simplify tedious, repetitive operations, boost profits across dentistry, and—most notably the level of care by validating diagnoses and removing significant amounts of ambiguity from the dental equation.

Oral Cancer Treatment Market Segment Insights

Oral Cancer Treatment Product Type Insights

The Oral Cancer Treatment Market segmentation, based on fusion product type, includes squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinomas, lymphomas. The squamous cell carcinoma segment held the majority share in 2022 contribution to significant share in respect to the Oral Cancer Treatment Market revenue. Squamous cell carcinoma is a type of cancer that can develop in various parts of the body, including the oral cavity and oropharynx, and is one of the most common types of oral cancer. Squamous cell carcinoma can cause a significant demand for oral cancer treatment for several reasons such as Aggressive nature, High incidence rate, Importance of early detection.

In 2019, the U.S. Food and Drug Administration (FDA) approved Libtayo for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) or metastatic CSCC in patients who are not candidates for curative surgery or curative radiation. Libtayo is a monoclonal antibody that blocks the activity of a protein called PD-1, which helps cancer cells evade the immune system.

In 2019, the FDA granted accelerated approval to Keytruda for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Keytruda is also a PD-1 inhibitor.

Oral Cancer Treatment Treatment Insights

The Oral Cancer Treatment Market segmentation, based on Treatment, includes surgery, radiation therapy, targeted therapy, chemotherapy, other treatments. The chemotherapy segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is due to the rising oral cancer cases, growing investment in healthcare sectors, technological and therapy development for chemotherapy that anticipated to support the market growth during forecast period.

In 2020 the U.S. Food and Drug Administration (FDA) granted accelerated approval to TECENTRIQ in combination with chemotherapy (carboplatin and etoposide) for the treatment of adults with extensive-stage small cell lung cancer, which can also be a form of oral cancer.

In 2019 the FDA approved Balversa for the treatment of metastatic or locally advanced urothelial carcinoma with specific genetic mutations. Urothelial carcinoma can occur in the bladder, ureters, and renal pelvis, which are part of the urinary system and can also be a form of oral cancer. Balversa is a kinase inhibitor and is administered orally.

Oral Cancer Treatment Application Insights

The Oral Cancer Treatment Market data has been bifurcated by application into hospitals and clinics, research organization, academic Institutes. The hospitals and clinics segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. One of the main applications of oral cancer therapies are hospitals and clinics. Because these tumours form inside the mouth and are not visible from the outside, oral cancers are typically discovered at a later stage. The early diagnosis of these tumours is therefore greatly aided by routine examinations and screenings by dentists or ENT specialists.

Figure 1: Oral Cancer Treatment Market, by Application, 2023 & 2032 (USD Billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

May 2023:Researchers at the Faculty of Dentistry at Dalhousie University are conducting one of the Faculty's first clinical trials to determine whether a drug commonly used to treat Type 2 diabetes could be effective in preventing oral cancer, a disease that disproportionately affects Atlantic Canadians. The research, a three-year chemotherapy prevention trial at Dalhousie, is conducted by the director of Dal's School of Hygiene and colleagues from nine other U.S. and Canadian institutions. They will recruit and examine patients with oral leukoplakia or erythroplakia, precancerous lesions in the mouth that can develop into cancer over time.

Oral Cancer Treatment Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Oral Cancer Treatment market accounted for USD 0.87 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed due to rising dental caries, increased regional awareness regarding how to treat dental caries, and technological advancements based on by the presence of major market players.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ORAL CANCER TREATMENT MARKET SHARE BY REGION 2022 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe oral cancer treatment market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an ageing population, and rising investment by private and public player in healthcare sector. Further, the Germany oral cancer treatment market held the largest market share, and the UK oral cancer treatment market was the fastest growing market in the European region

The Asia-Pacific Oral Cancer Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. The region's oral cancer treatment market is projected to be driven by rising tobacco use, rising smoking, a quickly growing patient population, a rapidly expanding health care industry, and high unmet needs. Also, during the forecast period, favorable government policies and an increase in disposable income are predicted to drive the oral cancer treatment market in the region. Moreover, China oral cancer treatment market held the largest market share, and the India oral cancer treatment market was the fastest growing market in the Asia-Pacific region

Oral Cancer Treatment Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the oral cancer treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the oral cancer treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global oral cancer treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, oral cancer treatment industry has provided medicine and treatment with some of the most significant benefits. The oral cancer treatment market major player such as Bristol-Myers Squibb Company (the U.S.), Merck & Co., Inc. (U.S.), Qilu Pharmaceutical Co., Ltd. (Asia Pacific) and others are working to expand the market demand by investing in research and development activities.

Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. BMS was founded in 1858 and is headquartered in New York City. BMS has a diverse portfolio of medicines that includes treatments for cancer, cardiovascular diseases, immunoscience, and fibrosis. Some of the company's most well-known drugs include Opdivo, Eliquis, Orencia, and Yervoy. In 2020, Bristol Myers Squibb announced that the FDA had granted accelerated approval for its drug OPDIVO (nivolumab) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. ESCC is a type of oral cancer that affects the lining of the esophagus.

Also, Merck & Co., Inc. (also known as MSD outside of the United States and Canada) is a global pharmaceutical company headquartered in New Jersey, USA. Merck is one of the largest pharmaceutical companies in the world, with a focus on developing, manufacturing, and marketing innovative medicines, vaccines, and animal health products. The company's areas of focus include oncology, vaccines, infectious diseases, neuroscience, and cardiovascular disease, among others. Merck is known for its research and development capabilities, as well as its commitment to advancing healthcare and improving patient outcomes. In 2021, Merck announced that it had received FDA approval for KEYTRUDA (pembrolizumab) in combination with chemotherapy for the treatment of locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinoma. GEJ cancer can be a form of oral cancer. Merck has also been involved in ongoing clinical trials for the treatment of oral cancer with KEYTRUDA.

Key Companies in the oral cancer treatment market includes

• Bristol-Myers Squibb Company ( U.S.)
• Qilu Pharmaceutical Co., Ltd. (Asia Pacific)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Eli Lilly and Company. (U.S.)
• F Hoffmann-La Roche Ltd (Europe)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Europe)
• Pfizer Inc. (U.S.), among others

Oral Cancer Treatment Industry Developments

In 2020 Bristol Myers Squibb announced that the FDA had granted accelerated approval for its drug OPDIVO (nivolumab) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. ESCC is a type of oral cancer that affects the lining of the esophagus.

In 2019 GlaxoSmithKline announced the FDA approval of its drug BLENREP (belantamab mafodotin-blmf) for the treatment of adult patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, which are found in the bone marrow and can also be a form of oral cancer. BLENREP is an antibody-drug conjugate that targets the BCMA protein, which is expressed on the surface of multiple myeloma cells.

Oral Cancer Treatment Market Segmentation

Oral Cancer Treatment Product Type Outlook

• Squamous Cell Carcinoma
• Verrucous Carcinoma
• Minor Salivary Gland Carcinomas
• Lymphomas

Oral Cancer Treatment Treatment Outlook

• Surgery
• Radiation Therapy
• Targeted Therapy
• Chemotherapy
• Other Treatments

Oral Cancer Treatment Application Outlook

• Hospitals And Clinics
• Research Organization
• Academic Institutes

Oral Cancer Treatment Regional Outlook

• North America

  • US
  • Canada

• Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe

• Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Australia
  • Rest of Asia-Pacific

• Rest of the World

  • Middle East

  • Africa

  • Latin America